These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16207147)

  • 41. Pharmacogenomics and individualized medicine: translating science into practice.
    Crews KR; Hicks JK; Pui CH; Relling MV; Evans WE
    Clin Pharmacol Ther; 2012 Oct; 92(4):467-75. PubMed ID: 22948889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine].
    Mushiroda T
    Rinsho Byori; 2013 May; 61(5):422-7. PubMed ID: 23947182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ontogeny and drug metabolism in newborns.
    Dotta A; Chukhlantseva N
    J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics: has the time come for pharmacists to embrace and implement the science?
    Beier MT; Panchapagesan M; Carman LE
    Consult Pharm; 2013 Nov; 28(11):696-711. PubMed ID: 24217190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
    O'Donnell PH; Bush A; Spitz J; Danahey K; Saner D; Das S; Cox NJ; Ratain MJ
    Clin Pharmacol Ther; 2012 Oct; 92(4):446-9. PubMed ID: 22929923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenomics: the promise of personalized medicine.
    Mancinelli L; Cronin M; Sadée W
    AAPS PharmSci; 2000; 2(1):E4. PubMed ID: 11741220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DMET microarray technology for pharmacogenomics-based personalized medicine.
    Burmester JK; Sedova M; Shapero MH; Mansfield E
    Methods Mol Biol; 2010; 632():99-124. PubMed ID: 20217574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenetics-based new therapeutic concepts.
    Roots I; Gerloff T; Meisel C; Kirchheiner J; Goldammer M; Kaiser R; Laschinski G; Brockmöller J; Cascorbi I; Kleeberg U; Hildebrandt AG
    Drug Metab Rev; 2004 Oct; 36(3-4):617-38. PubMed ID: 15554239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tailoring drug therapy based on genotype.
    Cavallari LH
    J Pharm Pract; 2012 Aug; 25(4):413-6. PubMed ID: 22907842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Drug therapy at the beginning of the genomic era].
    Stoica O; Braha E; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2002; 107(2):240-6. PubMed ID: 12638267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
    Steimer W
    Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
    Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
    Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HapMap, pharmacogenomics, and the goal of personalized prescribing.
    O'Shaughnessy KM
    Br J Clin Pharmacol; 2006 Jun; 61(6):783-6. PubMed ID: 16722846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.
    Squassina A; Manchia M; Manolopoulos VG; Artac M; Lappa-Manakou C; Karkabouna S; Mitropoulos K; Del Zompo M; Patrinos GP
    Pharmacogenomics; 2010 Aug; 11(8):1149-67. PubMed ID: 20712531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Customized drug therapy--how near is the goal?].
    Spigset O
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2390-6. PubMed ID: 16998553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.